目次

1. TIM3 - Emerging Immune Checkpoint
1.1 Introduction to TIM3 Inhibitor
1.2 Structure and Biology of TIM3

2. TIM3 as Cancer Combination Immunotherapy Target

3. Emerging TIM3 Inhibitors in Development

4. TIM3 Inhibitor Mechanism of Action
4.1 General Mechanism
4.2 Sabatolimab Proposed Mechanism of Action

5. Potential of TIM3 as Cancer Biomarker
5.1 TIM3 as Diagnostic Biomarker
5.2 TIM3 as Prognostic Biomarker

6. TIM3 Therapy Targeted Therapeutic Approach
6.1 Small Molecule Immunotherapy
6.2 Monoclonal Antibodies
6.3 Bispecific Antibodies

7. Global TIM3 Inhibitors Drugs Clinical Trials Overview
7.1 By Company
7.2 By Country
7.3 By Patient Segment/Disease Stage
7.4 By Phase

8. Global TIM3 Inhibitors Drugs Clinical Trials By Company, Indication and Phase
8.1 Preclinical
8.2 Phase-I
8.3 Phase-I/II
8.4 Phase-II
8.5 Phase-II/III
8.6 Phase-III

9. Application of TIM3 Targeted Therapy in Cancer
9.1 Myeloid Leukemia
9.2 Melanoma
9.3 Lung Cancer
9.4 Head and Neck Cancer

10. TIM3 Therapy Future Perspective
10.1 Clinical Forecast
10.2 Future Market Opportunity

11. Competitive Landscape
11.1 Agenus
11.2 AstraZeneca
11.3 Aurigene
11.4 BeiGene
11.5 BrightPath Therapeutics
11.6 Bristol Myers Squibb
11.7 Chia Tai Tianqing Pharmaceutical Group
11.8 Curis
11.9 Eli Lilly
11.10 GlaxoSmithKline
11.11 HanAll Biopharma
11.12 Incyte Corporation
11.13 Ligand Pharmaceuticals
11.14 Neologics Bio
11.15 Novartis
11.16 Roche
11.17 Sutro Biopharma
11.18 Symphogen
11.19 TrueBinding

List of Figures & Tables
Figure 1-1: Structure of TIM-3
Figure 4-1: Mechanism of Action of Anti-TIM-3 Antibodies
Figure 4-2: Sabatolimab - Mechanism of Action
Figure 7-1: Global - Number of TIM3 Inhibitors Drugs in Clinical Trials by Company, 2022 till 2028
Figure 7-2: Global - Number of TIM3 Inhibitors Drugs in Clinical Trials by Country, 2022 till 2028
Figure 7-3: Global - Number of TIM3 Inhibitors Drugs in Clinical Trials by Disease Stage, 2022 till 2028
Figure 7-4: Global - Number of TIM3 Inhibitors Drugs in Clinical Trials by Phase, 2022 till 2028
Figure 10-1: Global - TIM3 Inhibitor Market Opportunity by Approval Time (US$ Million), 2024 - 2028